A.R.T. Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

A.R.T. Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,272	Closed	-$62K	–	1115
2019 Q4	$62K	Sell	10,272 -71,100	-87%	-$486K	﹤0.01%	1243
2019 Q3	$615K	Buy	+81,372	New	+$917K	0.03%	773
2019 Q2	–	Sell	-18,388	Closed	-$100K	–	1708
2019 Q1	$100K	Buy	18,388 +7,802	+74%	+$38K	0.01%	1171
2018 Q4	$31K	Sell	10,586 -32,774	-76%	-$179K	﹤0.01%	1235
2018 Q3	$353K	Buy	43,360 +26,399	+156%	+$203K	0.02%	982
2018 Q2	$165K	Sell	16,961 -69,916	-80%	-$717K	0.01%	1258
2018 Q1	$754K	Buy	86,877 +21,879	+34%	+$236K	0.03%	772
2017 Q4	$813K	Sell	64,998 -69,125	-52%	-$792K	0.04%	704
2017 Q3	$1.12M	Buy	+134,123	New	+$1.42M	0.06%	483

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

A.R.T. Advisors's ZYNE Position: Q1 2020 in Review

A.R.T. Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2020, closing a stake of 10,272 shares — an estimated $62K sold.

A.R.T. Advisors first reported a position in ZYNE in Q3 2017 and held it in 9 quarters. The position peaked at $1.12M in Q3 2017. 77 funds tracked by Wall St. Rank hold ZYNE as of Q1 2020.

A.R.T. Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 10,272 Zynerba Pharmaceuticals, Inc shares in Q1 2020, an estimated $62K.
A.R.T. Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 9 quarters.
A.R.T. Advisors's Zynerba Pharmaceuticals, Inc position peaked at $1.12M in Q3 2017.
77 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.